SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
SciSparc receives FDA approval for trial for Tourette syndrome therapy [Yahoo! Finance]
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment [Yahoo! Finance]
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX [Yahoo! Finance]